HCA
IOVA icon

Harbor Capital Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Harbor Capital Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-90,267
Closed -$1.34M – 747
2024
Q1 		$1.34M Buy
90,267
+17,534
+24% +$204K 0.17% 154
2023
Q4 		$591K Buy
72,733
+7,870
+12% +$41.2K 0.11% 220
2023
Q3 		$295K Buy
64,863
+8,522
+15% +$55.6K 0.06% 310
2023
Q2 		$397K Buy
56,341
+5,172
+10% +$37K 0.08% 286
2023
Q1 		$313K Buy
51,169
+14,548
+40% +$100K 0.09% 184
2022
Q4 		$234K Sell
36,621
-780
-2% -$6.09K 0.23% 78
2022
Q3 		$358K Sell
37,401
-2,033
-5% -$23.4K 0.33% 70
2022
Q2 		$435K Sell
39,434
-2,749
-7% -$36K 0.33% 72
2022
Q1 		$702K Sell
42,183
-9,357
-18% -$145K 0.33% 72
2021
Q4 		$984K Buy
+51,540
New +$1.13M 0.36% 75

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Harbor Capital Advisors's IOVA Position: Q2 2024 in Review

Harbor Capital Advisors sold out of Iovance Biotherapeutics (IOVA) in Q2 2024, closing a stake of 90,267 shares — an estimated $1.34M sold.

Harbor Capital Advisors first reported a position in IOVA in Q4 2021 and held it in 10 quarters. The position peaked at $1.34M in Q1 2024. 295 funds tracked by Wall St. Rank hold IOVA as of Q2 2024.

  • Harbor Capital Advisors reported no remaining Iovance Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Harbor Capital Advisors sold 90,267 Iovance Biotherapeutics shares in Q2 2024, an estimated $1.34M.
  • Harbor Capital Advisors first reported a position in Iovance Biotherapeutics in Q4 2021 and held it in 10 quarters.
  • Harbor Capital Advisors's Iovance Biotherapeutics position peaked at $1.34M in Q1 2024.
  • 295 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2024.

Based on Harbor Capital Advisors's 13F filing for Q2 2024, filed 9 Jul 2024.